Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials
Liver International · 2025-09 · 45 (9)
DOI: 10.1111/liv.70256 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Liver International, online erschienen am 30.07.2025. Verfasst von Alessandro Mantovani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Aims There is uncertainty regarding the hepatic efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in metabolic dysfunction‐associated steatotic liver disease (MASLD) or steatohepatitis (MASH). We performed a meta‐analysis of randomised controlled trials (RCTs) to examine the efficacy of GLP‐1RAs in treating MASLD or MASH.
Methods
We systematically searched three electronic databases from inception until April 2025 to identify RCTs examining the efficacy of GLP‐1RAs for the treatment of MASLD or MASH. The outcome measures included MASH resolution without worsening of fibrosis or improvement in at least one stage of fibrosis without worsening of MASH, along with reductions in liver fat content measured using magnetic resonance‐based techniques. Meta‐analysis was conducted using random‐effects models.
Results
We identified 13 phase 2 or phase 3 RCTs (1811 participants). These trials diagnosed MASLD or MASH through liver biopsy ( n = 4) or magnetic resonance‐based techniques ( n = 9). Regardless of diabetes status, among individuals with MASH and moderate‐to‐advanced fibrosis, GLP‐1RAs (especially semaglutide 2.4 mg/week) for up to 72 weeks were superior to placebo in achieving MASH resolution ( n = 3 RCTs; pooled random‐effects odds ratio 3.48, 95% CI 2.69–4.51; I 2 = 0%), and in improving liver fibrosis (pooled odds ratio 1.79, 95% CI 1.37–2.35; I 2 = 0%). Among individuals with MASH‐related compensated cirrhosis ( n = 1 RCT available only), semaglutide did not lead to MASH resolution or improved fibrosis compared to placebo. Furthermore, GLP‐1RAs reduced magnetic resonance‐measured liver fat content ( n = 9; pooled mean difference: −4.50%, 95% CI −6.60 to −2.40%; I 2 = 95.9%).
Conclusions
GLP‐1RAs are a promising treatment option for MASLD or MASH. Further research is needed to evaluate the long‐term effects of GLP‐1RAs on liver‐related clinical events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy.
- Department of Medicine, University of Verona, Verona, Italy.
- Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephrology, University of Tübingen, Tübingen, Germany.
- Institute of Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich, Tübingen, Germany.
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria.
ORCID-Profile: Alessandro Mantovani, Norbert Stefan, Herbert Tilg, Christopher D Byrne, Giovanni Targher
Zitieren
APA
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Stefan, N., Tilg, H., Byrne, C. D., & Targher, G. (2025). Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials. Liver International, 45(9). https://doi.org/10.1111/liv.70256
Vancouver
Mantovani A, Morandin R, Fiorio V, Lando MG, Stefan N, Tilg H, et al. Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials. Liver International. 2025;45(9). doi:10.1111/liv.70256
BibTeX
@article{Mantovani2025,
author = {Mantovani, Alessandro and Morandin, Riccardo and Fiorio, Veronica and Lando, Maria Giovanna and Stefan, Norbert and Tilg, Herbert and Byrne, Christopher D and Targher, Giovanni},
title = {Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials},
journal = {Liver International},
year = {2025},
volume = {45},
number = {9},
doi = {10.1111/liv.70256}
}
EUVIMED